COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel
Claire J Han1, Ruth Kohen, Sangeun Jun
1Claire J. Han, PhD, RN, is Research Assistant, Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle. Ruth Kohen, MD, is Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, and Psychiatrist, Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington. Sangeun Jun, PhD, RN, is Assistant Professor, College of Nursing, Keimyung University, Daegu, South Korea. Monica E. Jarrett, PhD, RN, is Professor, Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle. Kevin C. Cain, PhD, is Research Scientist, Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle. Robert Burr, MSEE, PhD, is Research Professor, Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle. Margaret M. Heitkemper, PhD, RN, FAAN, is Professor, Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle.
Background:
Our nurse-delivered comprehensive self-management (CSM) program, a cognitive behavioral therapy intervention, is effective in reducing gastrointestinal and psychological distress symptoms in patients with irritable bowel syndrome (IBS). Findings from non-IBS studies indicate that the catechol-O-methyltransferase (COMT) Val158Met polymorphism may moderate the efficacy of cognitive behavioral therapy. It is unknown whether this COMT polymorphism is associated with symptom improvements in patients with IBS.
Objective:
We tested whether this COMT Val158Met polymorphism influences the efficacy of our 2-month CSM intervention.
Methods:
We analyzed data from two published randomized controlled trials of CSM. The combined European American sample included 149 women and 23 men with IBS (CSM, n = 111; usual care [UC], n = 61). The primary outcomes were daily reports of abdominal pain, depression, anxiety, and feeling stressed measured 3 and 6 months after randomization. Secondary outcomes were additional daily symptoms, retrospective psychological distress, IBS quality of life, and cognitive beliefs about IBS. The interaction between COMT Val158Met polymorphism and treatment group (CSM vs. UC) in a generalized estimating equation model tested the main objective.
Results:
At 3 months, participants with at least one Val allele benefited more from CSM than did those with the Met/Met genotype (p = .01 for anxiety and feeling stressed, and p < .16 for abdominal pain and depression). The moderating effect of genotype was weaker at 6 months.
Discussion:
Persons with at least one Val allele may benefit more from CSM than those homozygous for the Met allele. Future studies with larger and more racially diverse samples are needed to confirm these findings.
Rct Registration:
Parent studies were registered at ClinicalTrials.gov (NCT00167635 and NCT00907790).
More Related Videos
04:04Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
Published on: July 5, 2024
09:14Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging
Published on: March 14, 2025
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...